__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
HCP downloadable resources
Explore our growing repository of resources designed to provide useful information on SCEMBLIX and other relevant topics for healthcare professionals treating patients with CML.
SCEMBLIX MOA video
A video displaying the mechanism of action of SCEMBLIX, the first and only STAMP inhibitor, specifically targeting the ABL myristoyl pocket.1–3
Support booklet for patients on SCEMBLIX
This downloadable PDF can be shared with patients prescribed Scemblix with CP Ph+ CML, to provide further information about their condition and useful advice about taking SCEMBLIX.
Support groups for your patients
Leukaemia Care
Leukaemia Care is a national blood cancer support charity. For over 50 years the Leukaemia Care team have been dedicated to ensuring that everyone diagnosed with leukaemia and related blood cancer types receives the best possible diagnosis and treatment. The organization provides information, advice and support for patients, but also carers and families. Leukaemia Care team have created a variety of CML specific tools to help patients engage with the community and learn more about their diagnosis, including information booklets, support groups, webinars, as well as helpline, counselling and buddy programmes and other helpful platforms to support patients on their CML journey.
Blood Cancer UK
Can help you understand different types of blood cancer, including CML. Available information will let you know what you can expect at diagnosis, what treatment options are available and how to provide support to patients managing life with blood cancer.
CML Support
Originally established in 1999 by two patients diagnosed with Ph+ CML, CML Support patient advocacy group provides support, advice and up-to-date information about the disease and its treatment options to patients diagnosed with CML. CML Support is the UK’s only charity with an exclusive focus on people diagnosed with Ph+ CML and run by patients on a voluntary basis. The group works alongside healthcare professionals to help patients get the best and most appropriate care possible and maintains links with other patient groups worldwide.
As this site grows, we will be adding lots of new content. Sign up to receive our email communications and make sure you don’t miss the latest updates
CML, chronic myeloid leukaemia; MOA, mechanism of action; STAMP, specifically targeting the ABL1 myristoyl pocket.
SCEMBLIX is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia (Ph + CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors, and without a known T315I mutation.4
For further information please refer to the Summary of Product Characteristics.
References
- Réa D, et al. Blood 2021;138(21):2031–2041.
- Redaelli S, et al. J Clin Oncol 2009;27(3):469–471.
- Schoepfer J, et al. J Med Chem 2018;61(18):8120–8135.
- SCEMBLIX (asciminib) Summary of Product Characteristics.